332 related articles for article (PubMed ID: 10101581)
21. Disability as an outcome in MS clinical trials.
Ebers GC; Heigenhauser L; Daumer M; Lederer C; Noseworthy JH
Neurology; 2008 Aug; 71(9):624-31. PubMed ID: 18480462
[TBL] [Abstract][Full Text] [Related]
22. Analyzing the content of outcome measures in clinical trials on irritable bowel syndrome using the international classification of functioning, disability and health as a reference.
Schönrich S; Brockow T; Franke T; Dembski R; Resch KL; Cieza A
Rehabilitation (Stuttg); 2006 Jun; 45(3):172-80. PubMed ID: 16755436
[TBL] [Abstract][Full Text] [Related]
23. Issues affecting the selection of participation measurement in outcomes research and clinical trials.
Whiteneck GG
Arch Phys Med Rehabil; 2010 Sep; 91(9 Suppl):S54-9. PubMed ID: 20801281
[TBL] [Abstract][Full Text] [Related]
24. Efficacy endpoint selection and multiplicity adjustment methods in clinical trials with inherent multiple endpoint issues.
Sankoh AJ; D'Agostino RB; Huque MF
Stat Med; 2003 Oct; 22(20):3133-50. PubMed ID: 14518019
[TBL] [Abstract][Full Text] [Related]
25. Trial measures in multiple sclerosis: the use of magnetic resonance imaging in the evaluation of clinical trials.
Paty DW
Neurology; 1988 Jul; 38(7 Suppl 2):82-3. PubMed ID: 3386847
[No Abstract] [Full Text] [Related]
26. Are magnetic resonance findings predictive of clinical outcome in therapeutic trials in multiple sclerosis? The dilemma of interferon-beta.
McDonald WI; Miller DH; Thompson AJ
Ann Neurol; 1994 Jul; 36(1):14-8. PubMed ID: 8024255
[No Abstract] [Full Text] [Related]
27. Multiple sclerosis: use of MRI in evaluating new therapies.
Miller DH
Semin Neurol; 1998; 18(3):317-25. PubMed ID: 9817536
[TBL] [Abstract][Full Text] [Related]
28. Evaluating clinical trial data: outcome measures.
Conley RR
J Clin Psychiatry; 2001; 62 Suppl 9():23-6; discussion 27-8. PubMed ID: 11379827
[TBL] [Abstract][Full Text] [Related]
29. Examination of the role of MRI in multiple sclerosis: a problem orientated approach.
McFarland HF
Results Probl Cell Differ; 2010; 51():287-301. PubMed ID: 19960380
[TBL] [Abstract][Full Text] [Related]
30. Measuring outcomes in back care.
Carey TS; Mielenz TJ
Spine (Phila Pa 1976); 2007 May; 32(11 Suppl):S9-14. PubMed ID: 17495590
[TBL] [Abstract][Full Text] [Related]
31. Multiple sclerosis: epidemiology, genetics, classification, natural history, and clinical outcome measures.
Wingerchuk DM; Weinshenker BG
Neuroimaging Clin N Am; 2000 Nov; 10(4):611-24 ,vii. PubMed ID: 11359715
[TBL] [Abstract][Full Text] [Related]
32. [Roaming through methodology. XXV. Outcome measures, surrogate outcomes, and intermediate measures].
Boers M
Ned Tijdschr Geneeskd; 2000 Oct; 144(41):1949-52. PubMed ID: 11048558
[TBL] [Abstract][Full Text] [Related]
33. Outcome measures for clinical trials in multiple sclerosis.
Panitch HS
Ann Neurol; 1992 Jan; 31(1):116-7. PubMed ID: 1543345
[No Abstract] [Full Text] [Related]
34. How to participate in a multiple sclerosis clinical trial.
Frank JA; McFarland HF
Neuroimaging Clin N Am; 2000 Nov; 10(4):817-30 ,x. PubMed ID: 11359727
[TBL] [Abstract][Full Text] [Related]
35. [Evaluation of follow-up and evolution of multiple sclerosis].
Couvreur G
Rev Neurol (Paris); 2001 Sep; 157(8-9 Pt 2):1143-51. PubMed ID: 11787348
[TBL] [Abstract][Full Text] [Related]
36. Structural neuroimaging outcomes in clinical dementia trials, with special reference to disease modifying designs.
Scheltens P; Barkhof F
J Nutr Health Aging; 2006; 10(2):123-8; discussion 129-30. PubMed ID: 16554946
[TBL] [Abstract][Full Text] [Related]
37. [Development of antituberculous drugs: current status and future prospects].
Tomioka H; Namba K
Kekkaku; 2006 Dec; 81(12):753-74. PubMed ID: 17240921
[TBL] [Abstract][Full Text] [Related]
38. Emerging concepts in outcome assessment for COPD clinical trials.
Patel SA; Sciurba FC
Semin Respir Crit Care Med; 2005 Apr; 26(2):253-62. PubMed ID: 16088442
[TBL] [Abstract][Full Text] [Related]
39. Treatment optimisation in multiple sclerosis.
Zaffaroni M
Neurol Sci; 2005 Dec; 26 Suppl 4():S187-92. PubMed ID: 16388356
[TBL] [Abstract][Full Text] [Related]
40. Neuropsychological and MRI measures predict short-term evolution in benign multiple sclerosis.
Portaccio E; Stromillo ML; Goretti B; Zipoli V; Siracusa G; Battaglini M; Giorgio A; Bartolozzi ML; Guidi L; Sorbi S; Federico A; Amato MP; De Stefano N
Neurology; 2009 Aug; 73(7):498-503. PubMed ID: 19641173
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
